ADVERTISEMENT
LIVE DESK·Global markets desk·Last updated 14s ago
ADVERTISEMENT
Markets/EquitiesArticle

Wedbush lifts Best Buy price target to $85 on earnings outlook

Analyst upgrades rating to neutral as retailer’s shares gain 15% post-Q1, citing fiscal 2027 EPS estimate rise and domestic sales momentum ahead of August 27 report.

PA
Priya Anand · Equities & Earnings Desk · 24 Aug 2026 · 16:37 · 1 min read
Share
Wedbush lifts Best Buy price target to $85 on earnings outlook

Wedbush raised its price target for Best Buy to $85 from $75 while maintaining a neutral rating, citing optimism ahead of the consumer electronics retailer’s August 27 earnings release.

The firm’s valuation is based on 11.5 times its fiscal 2027 earnings per share estimate of $7.27, up from $7.16 previously. Best Buy currently trades at a trailing 12-month P/E of 16 and a PEG ratio of 0.5, according to InvestingPro, which assigns a fair value of $96.28.

Best Buy shares have climbed 15% since the company reported first-quarter results, outpacing the S&P 500’s 1.5% gain during the same period. Wedbush expects domestic comparable sales in the second quarter to rise between 2% and 3%, exceeding the consensus estimate of 1.9%. The company’s full-year comparable sales guidance ranges from a decline of 1% to growth of 1%, though Wedbush anticipates performance toward the upper end of that range.

The firm noted positive credit card data points suggesting potential upside, though it cautioned that management changes in the third quarter, rising computing prices, and tariff-related promotional pressures could limit the extent of any upward revision in guidance. Best Buy is scheduled to report second-quarter results before the market opens on August 27.

This article was produced with AI assistance and edited by a Finance Review Daily journalist.
ADVERTISEMENT
Share this story
PA
Written by
Priya Anand
Equities & Earnings Desk

Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.

More from Priya Anand →
ADVERTISEMENT
ADVERTISEMENT